NOVOGEN REPORTS DATA FOR INFLAMMATORY BOWEL DISEASE DRUG TRIAL

A Phase I clinical trial of Novogen's NV-52, an investigational drug to treat inflammatory bowel disease, has demonstrated rapid absorption indicating potential for development as an oral therapy.

NV-52 is a synthetic analogue based on the phenolic structure of naturally-occurring isoflavones, well known for their range of health benefits when consumed in certain foods and is undergoing development as an orally-delivered non-toxic agent for the maintenance of remission in inflammatory bowel disease.